Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
In order to keep on track with our fast evolution, our Website is getting a makeover.
Stay tuned to Discover MORE Than You Think!
Domain Therapeutics secures €6 million ($6.7M) debt financing"A few words from Pascal Neuville"
Domain Therapeutics obtient 6 millions d'euros de financement par l’emprunt
Pascal Neuville (CEO), Stanislas Malmezat (CFO) and Marjorie Sidhoum (Director of Business Operations) will be attending the JP Morgan Healthcare Conference. Come and meet them